OrthoPediatrics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

Core Viewpoint - OrthoPediatrics Corp. reported record financial results for the full year 2024, with total revenue of $204.7 million, a 38$52.7 million, a 40% increase from $37.6 million in Q4 2023, driven by growth in Global Trauma and Deformity, Scoliosis, and OPSB segments [4][7]. - Full year 2024 revenue reached$204.7 million, up 38% from $148.7 million in 2023, with U.S. revenue increasing by 45$161.2 million [5][7]. - Adjusted EBITDA for Q4 2024 was $3.0 million, compared to$1.3 million in Q4 2023, while full year adjusted EBITDA was $8.5 million, up from$5.0 million in 2023 [15][16]. Revenue Breakdown - U.S. revenue for Q4 2024 was $42.9 million, a 52$28.3 million in Q4 2023, representing 81% of total revenue [4][31]. - International revenue for Q4 2024 was $9.8 million, a 5$9.4 million in Q4 2023, accounting for 19% of total revenue [4][31]. - Trauma and Deformity revenue for Q4 2024 was $36.4 million, a 35$27.1 million in Q4 2023, while Scoliosis revenue increased by 62% to $15.6 million [6][31]. Operating Expenses - Total operating expenses for Q4 2024 were$49.6 million, a $14.8 million increase from$34.8 million in Q4 2023, primarily due to increased sales volume and the addition of Boston O&P [10][12]. - Sales and marketing expenses rose by 31.1% to $16.8 million in Q4 2024, while general and administrative expenses increased by 28.2$24.4 million [11][12]. Net Loss and Cash Flow - Net loss for Q4 2024 was $16.1 million, compared to a net loss of$6.7 million in Q4 2023, with net loss per share of $0.69 [15][16]. - The company reduced free cash flow usage by 70$235.0 million to $242.0 million, representing growth of 15% to 18% compared to 2024 [18].